Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc
Stephen Dale, Chief Medical Officer of Kura Oncology Inc, has sold 11,983 shares of the company on January 30, 2024, according to a recent SEC Filing. Kura Oncology Inc is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company's pipeline includes small molecule drug candidates that are designed to target key drivers of cancer in selected patient populations.
Over the past year, the insider has sold a total of 11,983 shares and has not made any purchases of the company's stock. The recent transaction is part of a series of insider activities at Kura Oncology Inc, which has seen 1 insider buy and 5 insider sells over the past year.
On the date of the insider's recent transaction, shares of Kura Oncology Inc were trading at $19.31 each, giving the company a market capitalization of $1.600 billion.
The insider's sale could be of interest to investors tracking insider behaviors as an indicator of company performance and potential stock movements. However, it is important to consider the broader context of the market and the company's fundamentals when evaluating the significance of insider transactions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
